Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19
NCT ID: NCT04534712
Last Updated: 2023-04-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2020-09-01
2021-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19
NCT04418206
Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection
NCT04707820
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
NCT04568044
Prognostic Value of IgM in Covid-19 Infection
NCT05092594
Description of Immunologic, Enzymatic and Metabolic Biomarkers Associated to the Severity of COVID-19 (SARS-CoV-2) and Its Resolution
NCT04664023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PROGRESSION
Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage
LYMPHOCYTE MONOCYTE RATIO
Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
NON PROGRESSION
Cohort B with those who improved by two points on the ordinal scale without any further progression
LYMPHOCYTE MONOCYTE RATIO
Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LYMPHOCYTE MONOCYTE RATIO
Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Sepsis
* Malignancy
* Patients on immunosuppressant therapy
* Chronic inflammatory conditions
* Cases lost to follow up
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sir Ganga Ram Hospital
OTHER
Post Graduate Institute of Medical Education and Research, Chandigarh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
VAMSIDHAR
DNB Trainee
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
yet to be assigned
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.